JPWO2013161871A1 - Ｔｌｒ阻害作用を有するチオフェン誘導体 - Google Patents

Ｔｌｒ阻害作用を有するチオフェン誘導体 Download PDF

Info

Publication number
JPWO2013161871A1
JPWO2013161871A1 JP2014512646A JP2014512646A JPWO2013161871A1 JP WO2013161871 A1 JPWO2013161871 A1 JP WO2013161871A1 JP 2014512646 A JP2014512646 A JP 2014512646A JP 2014512646 A JP2014512646 A JP 2014512646A JP WO2013161871 A1 JPWO2013161871 A1 JP WO2013161871A1
Authority
JP
Japan
Prior art keywords
group
ring
alkyl group
phenyl
thiophen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014512646A
Other languages
English (en)
Japanese (ja)
Inventor
俊司 竹村
俊司 竹村
達明 西山
達明 西山
裕一朗 天竺桂
裕一朗 天竺桂
正毅 山火
正毅 山火
章泰 纐纈
章泰 纐纈
宙久 徳田
宙久 徳田
祥元 三宅
祥元 三宅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Priority to JP2014512646A priority Critical patent/JPWO2013161871A1/ja
Publication of JPWO2013161871A1 publication Critical patent/JPWO2013161871A1/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
JP2014512646A 2012-04-25 2013-04-24 Ｔｌｒ阻害作用を有するチオフェン誘導体 Pending JPWO2013161871A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014512646A JPWO2013161871A1 (ja) 2012-04-25 2013-04-24 Ｔｌｒ阻害作用を有するチオフェン誘導体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2012099748 2012-04-25
JP2012099748 2012-04-25
JP2012178787 2012-08-10
JP2012178787 2012-08-10
JP2014512646A JPWO2013161871A1 (ja) 2012-04-25 2013-04-24 Ｔｌｒ阻害作用を有するチオフェン誘導体

Publications (1)

Publication Number Publication Date
JPWO2013161871A1 true JPWO2013161871A1 (ja) 2015-12-24

Family

ID=49483179

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014512646A Pending JPWO2013161871A1 (ja) 2012-04-25 2013-04-24 Ｔｌｒ阻害作用を有するチオフェン誘導体

Country Status (2)

Country Link
JP (1) JPWO2013161871A1 (fr)
WO (1) WO2013161871A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CN111788204B (zh) 2018-02-26 2023-05-05 吉利德科学公司 作为hbv复制抑制剂的取代吡咯嗪化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939332A (en) * 1998-02-27 1999-08-17 Roche Diagnostics Corp. Phencyclidine analogs for immunoassay
PT957099E (pt) * 1998-04-15 2003-02-28 Pfizer Prod Inc Carboxamidas heterociclicas
AU776053B2 (en) * 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
WO2002016355A2 (fr) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Fragments heteroaryle a substitution quinuclidine destines au traitement de maladies
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1419161A1 (fr) * 2001-08-24 2004-05-19 PHARMACIA & UPJOHN COMPANY Heteroaryl-7-aza 2.2.1]bicycloheptanes substitues destines au traitement de maladies
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
GB0406280D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Chemical compounds
RU2006138036A (ru) * 2004-03-30 2008-05-10 Чирон Корпорейшн (Us) Производные замещенного тиофена в качестве противораковых средств
US7759337B2 (en) * 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
EP2083816A2 (fr) * 2006-10-27 2009-08-05 Brystol-Myers Squibb Company Composés d'amide hétérocyclique utiles comme inhibiteurs de kinase
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
EP2070924A1 (fr) * 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Nouveaux dérivés de 2-hetarylthiazol-4-amides d'acide carboxylique, leur fabrication et leur utilisation en tant que médicament
EP2070925A1 (fr) * 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Nouveaux dérivés de 2-thiazol-4-amides d'acide carboxylique substitués, leur fabrication et leur utilisation en tant que médicament
EP2070916A1 (fr) * 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Dérivés de 2-aryl-thiazol-4-amides d'acide carboxylique, leur fabrication et leur utilisation en tant que médicament

Also Published As

Publication number Publication date
WO2013161871A1 (fr) 2013-10-31

Similar Documents

Publication Publication Date Title
KR102057366B1 (ko) 치환된 벤젠 화합물
US8067457B2 (en) Compounds useful as antagonists of CCR2
JP5736507B2 (ja) 含窒素複素環化合物またはその塩
US10287255B2 (en) Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
AU2012221927B2 (en) Diaminopyrimidine derivatives and processes for the preparation thereof
US20090149460A1 (en) New Compounds
KR20030026979A (ko) 디시아노피리딘 유도체를 포함하는 의약
TWI647227B (zh) ２－醯胺噻唑衍生物或其鹽
WO2004108715A1 (fr) Benzo[b]thiophenes a substitution 3-aryloxy et 3-heteroaryloxy en tant qu'agents therapeutiques a activite pi3k
KR101383538B1 (ko) Ｎｋ3 수용체 길항제로서 피페리딘 유도체
US20120208818A1 (en) Compounds useful as antagonists of ccr2
JP4426284B2 (ja) ピロリジン・オキサジアゾール−及びチアジアゾール誘導体
WO2013161871A1 (fr) Dérivé de thiophène ayant une activité inhibitrice de tlr
WO2014034719A1 (fr) Dérivé de quinoline possédant une activité inhibitrice de tlr
WO2013108837A1 (fr) Dérivé de pyrazole doté de propriétés inhibitrices de tlr
JP7386576B2 (ja) Ｎ－（１ｈ－イミダゾール－２－イル）ベンズアミド化合物および該化合物を活性成分として含む医薬組成物
JP2013091624A (ja) Ｔｌｒ阻害作用を有するキナゾリン誘導体
EP4110758A1 (fr) Composés hétérocycliques pour la modulation de nr2f6
WO2013180066A1 (fr) Dérivé de pyridine ayant un effet inhibiteur sur le tlr
RU2720205C2 (ru) Азотсодержащее гетероциклическое соединение
JP2014148491A (ja) Ｔｌｒ阻害作用を有するチアゾール誘導体
RU2806754C1 (ru) N-(1h-имидазол-2-ил)бензамид и содержащая его фармацевтическая композиция в качестве активного ингредиента
JP2014118401A (ja) Ｔｌｒ阻害作用を有するフラン誘導体
JP2014101314A (ja) Ｔｌｒ阻害作用を有するピロール誘導体
JP2010533685A (ja) ピラゾール３，５カルボキシレート誘導体、これらの調製および治療上の適用